Diversified Healthcare Trust
Diversified Healthcare Trust's revenue rose 2.8% to $1.5 billion in fiscal 2025. Its net margin was −18.6%, up from −24.8% a year earlier. Free cash flow was −$166 million. It paid out $11 million in dividends and buybacks. The diluted share count rose 0.3%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Diversified Healthcare Trust does
Diversified Healthcare Trust is a real estate investment trust that owns healthcare properties. Its main holdings are senior living communities, including active adult communities, and medical office and life science buildings.
It earns money from rent and from the operations of its senior living communities. It does not run the communities itself but depends on managers and other operators. It also owns stakes in two joint ventures that hold medical office and life science properties in five states.
It says the aging of the U.S. population and growth in healthcare spending support demand for its properties.
It reports its senior living business in a segment it calls SHOP, and reports its other properties separately.
Its biggest risks, as it describes them
- Unfavorable market and industry conditions that have hurt, and may keep hurting, its results.
- Its debt, and failing to meet the terms of its debt agreements.
- Secured debt that exposes it to foreclosure.
- Depending on managers and operators to run its senior living communities.
- Higher labor costs and staff turnover at its managers, and residents leaving.
Income statement
From fiscal 2016 to 2021, earnings per share grew 4.0% a year and net income 4.3% a year, with the share count about the same. Diversified Healthcare Trust then lost money in fiscal 2022, 2023, 2024 and 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 635 | 658 | 246 | 145 | 105 |
| Debt incl. finance leases | 7 | 5 | 4 | 3,053 | 2,445 |
| Net debt (negative means net cash) | −628 | −653 | −242 | 2,908 | 2,339 |
| Net debt to EBITDA | −0.9x | −1.5x | −1.2x | 19.5x | 16.1x |
| Debt to equity | 0.0x | 0.0x | 0.0x | 1.6x | 1.5x |
| Interest coverage | 1.7x | 0.9x | −0.4x | −0.6x | −0.6x |
| Current ratio | — | — | — | — | — |
| Quick ratio | — | — | — | — | — |
Cash flow
Projections
Project Diversified Healthcare Trust's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $97,800 of Diversified Healthcare Trust shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Dec 15, 2025 | Christopher J. BilottoPresident and CEO, Director | Bought | 20,000 | $4.89 | $97,800 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −6.0% | 0.1% | −8.0% |
| Altman Z'' | — | — | — |
| Accruals ratio | −5.3% | −9.1% | −5.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Pass | Pass | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Pass |
| Current ratio rose | — | — | — |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put Diversified Healthcare Trust side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Diversified Healthcare Trust | FY25 | 2.8% | — | −10.8% | −2.1% | 16.1x | — | |
| Omega Healthcare Investors | FY25 | 13.2% | — | 67.0% | 8.8% | 3.6x | — | Compare |
| Healthcare Realty Trust | FY25 | −6.9% | — | 10.8% | — | — | — | Compare |
| American Healthcare REIT | FY25 | 9.2% | 18.4% | — | — | — | — | Compare |
| Medical Properties Trust | FY25 | −2.4% | — | — | 1.6% | 16.8x | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 1,058 | 1,075 | 1,117 | 1,040 | 1,632 | 1,383 | 1,284 | 1,410 | 1,495 | 1,538 |
| Revenue growth | 5.9% | 1.6% | 3.9% | −6.9% | 56.9% | −15.2% | −7.2% | 9.9% | 6.0% | 2.8% |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | — | — | — | — | — | — | — | — | — | — |
| Operating income | 303 | 275 | — | — | — | — | — | — | — | — |
| Net income | 141 | 148 | 287 | −88 | −140 | 174 | −16 | −294 | −370 | −286 |
| Diluted EPS (US$) | 0.60 | 0.62 | 1.21 | −0.37 | −0.59 | 0.73 | −0.07 | −1.23 | −1.55 | −1.19 |
| Diluted shares (millions) | 237 | 238 | 238 | 238 | 238 | 238 | 238 | 239 | 240 | 240 |
| Cash flow | ||||||||||
| Cash from operations | 424 | 419 | 393 | 266 | 158 | −63 | −40 | 10 | 112 | −20 |
| Capital expenditure | 100 | 117 | 104 | 222 | 186 | 228 | 299 | 235 | 202 | 147 |
| Free cash flow | 325 | 302 | 289 | 43 | −27 | −291 | −340 | −225 | −89 | −166 |
| Dividends paid | 370 | 371 | 371 | 200 | 43 | 10 | 10 | 10 | 10 | 10 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 3 | 3 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 32 | 31 | 55 | 37 | 74 | 635 | 658 | 246 | 145 | 105 |
| Debt incl. finance leases | 547 | 548 | 3,684 | 449 | 207 | 7 | 5 | 4 | 3,053 | 2,445 |
| Total assets | 7,228 | 7,294 | 7,160 | 6,654 | 6,476 | 6,624 | 6,002 | 5,446 | 5,137 | 4,361 |
| Total liabilities | 4,028 | 4,017 | 3,981 | 3,777 | 3,857 | 3,961 | 3,364 | 3,109 | 3,178 | 2,696 |
| Shareholders' equity | 3,199 | 3,105 | 3,023 | 2,736 | 2,496 | 2,662 | 2,639 | 2,337 | 1,959 | 1,666 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | 28.6% | 25.6% | — | — | — | — | — | — | — | — |
| Net margin | 13.3% | 13.7% | 25.7% | −8.5% | −8.5% | 12.6% | −1.2% | −20.8% | −24.8% | −18.6% |
| Free cash flow margin | 30.7% | 28.1% | 25.9% | 4.2% | −1.7% | −21.0% | −26.5% | −15.9% | −6.0% | −10.8% |
| Rule of 40 (growth + FCF margin) | 36.6% | 29.7% | 29.8% | −2.7% | 55.2% | −36.3% | −33.7% | −6.0% | 0.1% | −8.0% |
| Return on capital | 8.0% | 7.3% | 8.9% | 1.5% | 1.8% | 18.1% | 7.4% | −3.1% | −3.1% | −2.1% |
| Return on equity | 4.3% | 4.7% | 9.4% | −3.1% | −5.3% | 6.8% | −0.6% | −11.8% | −17.2% | −15.8% |
| Return on assets | 2.0% | 2.0% | 4.0% | −1.3% | −2.1% | 2.7% | −0.2% | −5.1% | −7.0% | −6.0% |
| Net debt to EBITDA | 0.9x | 0.9x | 4.8x | 1.1x | 0.4x | −0.9x | −1.5x | −1.2x | 19.5x | 16.1x |